{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:04:40Z","timestamp":1794362680878,"version":"4.9.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0195897","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T15:11:53Z","timestamp":1523632313000},"page":"e0195897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":65,"title":["Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial"],"prefix":"10.1371","volume":"13","author":[{"given":"Edgar Turner","family":"Overton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-9715","authenticated-orcid":true,"given":"Katrin","family":"Nopora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kreusel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"De Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Weidenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaly","family":"Samy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"ref1","first-page":"1263","article-title":"The confirmation and maintenance of smallpox eradication","volume":"303","author":"JG Breman","year":"1980"},{"key":"ref2","first-page":"423","article-title":"Smallpox vaccination and bioterrorism with pox viruses","volume":"26","author":"A Mayr","year":"2003"},{"key":"ref3","first-page":"1225","article-title":"Smallpox vaccines for biodefense: need and feasibility","volume":"7","author":"AW Artenstein","year":"2008"},{"key":"ref4","first-page":"303","article-title":"Complications of smallpox vaccination, 1968: results of ten statewide surveys","volume":"122","author":"JM Lane","year":"1970"},{"key":"ref5","first-page":"4758","article-title":"Ischemic cardiac events and other adverse events following ACAM2000(\u00ae) smallpox vaccine in the Vaccine Adverse Event Reporting System","volume":"32","author":"MM McNeil","year":"2014"},{"key":"ref6","first-page":"642","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"MK Arness","year":"2004"},{"key":"ref7","first-page":"3283","article-title":"Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel","volume":"289","author":"JS Halsell","year":"2003"},{"key":"ref8","first-page":"291","article-title":"A report of 2 cases of myopericarditis after Vaccinia virus (smallpox) immunization","volume":"110","author":"U Sharma","year":"2011"},{"key":"ref9","first-page":"615","article-title":"Cardiac complications after smallpox vaccination","volume":"102","author":"LF Mora","year":"2009"},{"key":"ref10","first-page":"7442","article-title":"Modified Vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"M Suter","year":"2009"},{"key":"ref11","first-page":"7845","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"KJ Stittelaar","year":"2005"},{"key":"ref12","first-page":"e0157335","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN<sup>\u00ae<\/sup>) in 56-80-Year-Old Subjects","volume":"11","author":"RN Greenberg","year":"2016"},{"key":"ref13","first-page":"e0122653","article-title":"Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population","volume":"10","author":"EM Zitzmann-Roth","year":"2015"},{"key":"ref14","first-page":"749","article-title":"Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects","volume":"207","author":"RN Greenberg","year":"2013"},{"key":"ref15","article-title":"Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial","volume":"2","author":"ET Overton","year":"2015"},{"key":"ref16","first-page":"5696","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"F Von Sonnenburg","year":"2014"},{"key":"ref17","first-page":"e0138348","article-title":"A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18\u201340 Year Old Subjects with Diagnosed Atopic Dermatitis","volume":"10","author":"RN Greenberg","year":"2015"},{"key":"ref18","first-page":"8562","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE<sup>\u00ae<\/sup> (Modified Vaccinia Ankara) followed by Dryvax<sup>\u00ae<\/sup> challenge","volume":"25","author":"SE Frey","year":"2007"},{"key":"ref19","first-page":"2732","article-title":"Phase II randomised, double-blinded comparison of a single high dose (5\u00d710<sup>8<\/sup> TCID<sub>50<\/sub>) of modified vaccinia Ankara compared to a standard dose (1\u00d710<sup>8<\/sup> TCID<sub>50<\/sub>) in healthy vaccinia-na\u00efve individuals","volume":"32","author":"SE Frey","year":"2014"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomised, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE<sup>\u00ae<\/sup>","volume":"28","author":"A Von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"key":"ref21","first-page":"5225","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na\u00efve subjects","volume":"33","author":"SE Frey","year":"2015"},{"key":"ref22","first-page":"2065","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"J Vollmar","year":"2006"},{"key":"ref23","article-title":"Non-inferior immunogenicity and comparable safety and tolerability of a new freeze-dried compared to the current liquid frozen formulation of the non-replicating smallpox vaccine MVA-BN<sup>\u00ae<\/sup>","author":"RN Greenberg","journal-title":"Manuscript in preparation"},{"key":"ref24","first-page":"e54407","article-title":"Prospective surveillance for cardiac adverse events in healthy adults receiving Modified Vaccinia Ankara vaccines: a systematic review","volume":"8","author":"M Elizaga","year":"2013"},{"key":"ref25","first-page":"184","article-title":"Feasibility and usefulness of troponin I testing in insurance medicine","volume":"44","author":"L Haldiman","year":"2014"},{"key":"ref26","first-page":"322","article-title":"Morphological abnormalities in baseline ECGs in healthy normal volunteers participating in phase I studies","volume":"135","author":"P Hingorani","year":"2012"},{"key":"ref27","first-page":"636","article-title":"Prevalence and prognosis of electrocardiographic findings in middle-aged men","volume":"40","author":"G Rose","year":"1978"},{"key":"ref28","article-title":"Pharmacotherapy Update of Acute Idiopathic Pericarditis","volume":"35","author":"N Schwier","year":"2015"},{"key":"ref29","unstructured":"ACAM2000 Vaccines and Related Biological Products. Advisory Committee (VRBPAC) Briefing Document (April 2007) <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4292B2-00-index.html\" xlink:type=\"simple\">http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4292B2-00-index.html<\/ext-link> (accessed September 1, 2016)."},{"key":"ref30","first-page":"e0118283","article-title":"A prospective study of the incidence of myocarditis\/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination","volume":"10","author":"RJM Engler","year":"2015"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0195897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:59:46Z","timestamp":1540342786000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0195897"}},"subtitle":[],"editor":[{"given":"Stephen R.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0195897","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.t003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.t004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0195897.s004","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]}}}